160 related articles for article (PubMed ID: 23250739)
1. Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII.
Gururaj AE; Gibson L; Panchabhai S; Bai M; Manyam G; Lu Y; Latha K; Rojas ML; Hwang Y; Liang S; Bogler O
J Biol Chem; 2013 Feb; 288(5):3428-38. PubMed ID: 23250739
[TBL] [Abstract][Full Text] [Related]
2. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
[TBL] [Abstract][Full Text] [Related]
3. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
[TBL] [Abstract][Full Text] [Related]
4. Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity.
Hwang Y; Chumbalkar V; Latha K; Bogler O
Mol Cancer Res; 2011 Sep; 9(9):1199-208. PubMed ID: 21775422
[TBL] [Abstract][Full Text] [Related]
5. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
Mukasa A; Wykosky J; Ligon KL; Chin L; Cavenee WK; Furnari F
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2616-21. PubMed ID: 20133782
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.
Bonavia R; Inda MM; Vandenberg S; Cheng SY; Nagane M; Hadwiger P; Tan P; Sah DW; Cavenee WK; Furnari FB
Oncogene; 2012 Sep; 31(36):4054-66. PubMed ID: 22139077
[TBL] [Abstract][Full Text] [Related]
7. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation.
Perini G; Diolaiti D; Porro A; Della Valle G
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12117-22. PubMed ID: 16093321
[TBL] [Abstract][Full Text] [Related]
8. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
[No Abstract] [Full Text] [Related]
9. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells.
Huang A; Ho CS; Ponzielli R; Barsyte-Lovejoy D; Bouffet E; Picard D; Hawkins CE; Penn LZ
Cancer Res; 2005 Jul; 65(13):5607-19. PubMed ID: 15994933
[TBL] [Abstract][Full Text] [Related]
10. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.
Sabò A; Kress TR; Pelizzola M; de Pretis S; Gorski MM; Tesi A; Morelli MJ; Bora P; Doni M; Verrecchia A; Tonelli C; Fagà G; Bianchi V; Ronchi A; Low D; Müller H; Guccione E; Campaner S; Amati B
Nature; 2014 Jul; 511(7510):488-492. PubMed ID: 25043028
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.
Lustig LC; Dingar D; Tu WB; Lourenco C; Kalkat M; Inamoto I; Ponzielli R; Chan WCW; Shin JA; Penn LZ
Oncogene; 2017 Dec; 36(49):6830-6837. PubMed ID: 28806396
[TBL] [Abstract][Full Text] [Related]
12. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells.
Jaganathan S; Yue P; Paladino DC; Bogdanovic J; Huo Q; Turkson J
PLoS One; 2011 May; 6(5):e19605. PubMed ID: 21573184
[TBL] [Abstract][Full Text] [Related]
13. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
Murphy DM; Buckley PG; Bryan K; Das S; Alcock L; Foley NH; Prenter S; Bray I; Watters KM; Higgins D; Stallings RL
PLoS One; 2009 Dec; 4(12):e8154. PubMed ID: 19997598
[TBL] [Abstract][Full Text] [Related]
14. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
Inda MM; Bonavia R; Mukasa A; Narita Y; Sah DW; Vandenberg S; Brennan C; Johns TG; Bachoo R; Hadwiger P; Tan P; Depinho RA; Cavenee W; Furnari F
Genes Dev; 2010 Aug; 24(16):1731-45. PubMed ID: 20713517
[TBL] [Abstract][Full Text] [Related]
15. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
Choe C; Chen N; Sawadogo M
Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
[TBL] [Abstract][Full Text] [Related]
16. Menin enhances c-Myc-mediated transcription to promote cancer progression.
Wu G; Yuan M; Shen S; Ma X; Fang J; Zhu L; Sun L; Liu Z; He X; Huang D; Li T; Li C; Wu J; Hu X; Li Z; Song L; Qu K; Zhang H; Gao P
Nat Commun; 2017 May; 8():15278. PubMed ID: 28474697
[TBL] [Abstract][Full Text] [Related]
17. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR.
Chumbalkar V; Latha K; Hwang Y; Maywald R; Hawley L; Sawaya R; Diao L; Baggerly K; Cavenee WK; Furnari FB; Bogler O
J Proteome Res; 2011 Mar; 10(3):1343-52. PubMed ID: 21214269
[TBL] [Abstract][Full Text] [Related]
18. MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation.
Stojanova A; Tu WB; Ponzielli R; Kotlyar M; Chan PK; Boutros PC; Khosravi F; Jurisica I; Raught B; Penn LZ
Cell Cycle; 2016 Jul; 15(13):1693-705. PubMed ID: 27267444
[TBL] [Abstract][Full Text] [Related]
19. MYC phosphorylation at novel regulatory regions suppresses transforming activity.
Wasylishen AR; Chan-Seng-Yue M; Bros C; Dingar D; Tu WB; Kalkat M; Chan PK; Mullen PJ; Huang L; Meyer N; Raught B; Boutros PC; Penn LZ
Cancer Res; 2013 Nov; 73(21):6504-15. PubMed ID: 24030976
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
Lo HW; Cao X; Zhu H; Ali-Osman F
Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
